Entrada Therapeutics (TRDA) Total Current Liabilities (2020 - 2026)

Entrada Therapeutics' Total Current Liabilities history runs 7 years deep, the most recent figure standing at $19.2 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 4.15% year-over-year to $19.2 million; the TTM figure through Mar 2026 stood at $19.2 million (up 4.15% YoY), while the FY2025 annual figure was $24.5 million, down 38.07% from the prior year.
• Total Current Liabilities was $19.2 million for Q1 2026 at Entrada Therapeutics, down from $24.5 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $173.9 million in Q1 2024 to a low of $15.4 million in Q1 2022.
• Historically, Total Current Liabilities has averaged $67.7 million across 5 years, with a median of $24.5 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Total Current Liabilities surged 856.79% in 2023, then tumbled 89.4% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $22.0 million in 2022, then soared by 622.72% to $158.8 million in 2023, then tumbled by 75.14% to $39.5 million in 2024, then slumped by 38.07% to $24.5 million in 2025, then decreased by 21.5% to $19.2 million in 2026.
• The last three Total Current Liabilities figures came in at $19.2 million (Q1 2026), $24.5 million (Q4 2025), and $24.0 million (Q3 2025), per Business Quant data.